TITLE

HCV chronic hepatitis in patients with HIV: clinical management issues

AUTHOR(S)
Bruno, Raffaele; Sacchi, Paolo; Puoti, Massimo; Soriano, Vincente; Filice, Gaetano
PUB. DATE
July 2002
SOURCE
American Journal of Gastroenterology;Jul2002, Vol. 97 Issue 7, p1598
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
HIV-hepatitis C virus (HCV) coinfection is common and affects more than one-third of all HIV infected persons worldwide. Prevalence among risk categories varies according to shared risk factors for transmission, mainly intravenous drug use (IDU) and hemophiliacs. Chronic HCV infection seems to accelerate the course of HIV disease, resulting in a worsened clinical and immunological progression. At the same time, several studies suggest that HIV disease modifies the natural history of HCV infection, leading to a faster course of progression from active hepatitis to cirrhosis, to end stage liver disease and death. HCV infection mimics opportunistic diseases because its natural history is significantly accelerated in HIV patients. Since highly active antiretroviral therapy (HAART) has slowed the progression of HIV disease and decreased the rate of HIV associated mortality, the prognosis of HIV disease has been modified, and the need to treat HCV coinfection become a significant issue. Because of the poor response rate obtained by either interferon alone or interferon thrice weekly plus ribavirin, the combination of pegylated interferon and ribavirin will probably become the standard of care, although the clinicians should be aware of the overlapping toxicity of nucleoside analogues and ribavirin. Many selected categories of patients pose particular challenges to physicians treating HCV infection: nonresponders to interferon, cirrhotic patients, and patients infected with both HCV and HBV. Liver transplantation in HIV patients is currently under evaluation, but should become the rescue therapy for HIV patients with end stage liver disease.
ACCESSION #
7839721

 

Related Articles

  • A Weak Neutralizing Antibody Response to Hepatitis C Virus Envelope Glycoprotein Enhances Virus Infection. Meyer, Keith; Banerjee, Arup; Frey, Sharon E.; Belshe, Robert B.; Ray, Ranjit // PLoS ONE;2011, Vol. 6 Issue 8, p1 

    We have completed a phase 1 safety and immunogenicity trial with hepatitis C virus (HCV) envelope glycoproteins, E1 and E2, with MF59 adjuvant as a candidate vaccine. Neutralizing activity to HCV genotype 1a was detected in approximately 25% of the vaccinee sera. In this study, we evaluated...

  • EFIKASNOST ANTIVIRUSNE TERAPIJE KOD OSOBA SA HEMOFILIJOM I HEPATITIS C VTRUSNOM INFEKCIJOM. KOSTIĆ, Velimir; ĐORĐEVIĆ, Marina; PPOPOVIĆ, Lidija; KOSTIĆ, Emina; ĐORĐEVIiĆ, Jovana; GOVEDAREVIĆ, Nenad // Medicinski Pregled / Medical Review;2009, Vol. 62 Issue 3/4, p129 

    INTRODUCTION: HCV infection was common cause of morbidity and mortality in patients with hemophilia before 1986. We wanted to investigate the effect of treatment with combination therapy in HCV positive patients with hemophilia. MATERIAL AND METHODS: The research included totally 13 persons...

  • Hepatitis C Virus and Lichen Planus: The Real Association. Mahboobi, Nima; Agha-Hosseini, Farzaneh; Lankarani, Kamran Bagheri // Hepatitis Monthly;Summer2010, Vol. 10 Issue 3, p161 

    The authors reflect on the relationship between hepatitis C virus (HCV) and oral lichen planus (OLP). They state that HCV is a single-stranded RNA virus which has extremely variable genomes, with six distinct genotypes. Meanwhile, OLP was linked with several viral infections including...

  • Renal transplantation in patients with hepatitis C virus antibody. A long national experience. Morales, Jose María; Marcén, Roberto; Andres, Amado; Domínguez-Gil, Beatriz; Campistol, Josep María; Gallego, Roberto; Gutierrez, Alex; Gentil, Miguel Angel; Oppenheimer, Federico; Samaniego, María Luz; Muñoz-Robles, Jorge; Serón, Daniel // NDT Plus;Jun2010 Supplement 2, Vol. 3 Issue suppl_2, pii41 

    Background. Renal transplantation is the best therapy for patients with hepatitis C virus (HCV) infection with end-stage renal disease. Patient and graft survival are lower in the long term compared with HCV-negative patients. The current study evaluated the results of renal transplantation in...

  • Deconvoluting the Composition of Low-Frequency Hepatitis C Viral Quasispecies: Comparison of Genotypes and NS3 Resistance-Associated Variants between HCV/HIV Coinfected Hemophiliacs and HCV Monoinfected Patients in Japan. Ogishi, Masato; Yotsuyanagi, Hiroshi; Tsutsumi, Takeya; Gatanaga, Hiroyuki; Ode, Hirotaka; Sugiura, Wataru; Moriya, Kyoji; Oka, Shinichi; Kimura, Satoshi; Koike, Kazuhiko // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Pre-existing low-frequency resistance-associated variants (RAVs) may jeopardize successful sustained virological responses (SVR) to HCV treatment with direct-acting antivirals (DAAs). However, the potential impact of low-frequency (∼0.1%) mutations, concatenated mutations (haplotypes), and...

  • Impact of Observer Experience on the Reproducibility of Transient Elastometry in HIV/HCV Co-infected Patients. Karin Neukam; Juan Macías; Concepción Ferrete; José Palomares; Ana Fernández; José Mira; Juan Pineda // HIV Clinical Trials;Jul2009, Vol. 10 Issue 4, p276 

    Background: Data on the influence of observer experience on transient elastometry (TE) in hepatitis C virus (HCV) infection are scarce, and there are no data on HCV/HIV co-infected patients. Methods: TE determination was conducted by an experienced and an inexperienced observer in 93 patients...

  • Consensus interferon: tailored therapy and the impact of adherence. Gonzalez, Stevan; Gonzalez, Stevan A // Digestive Diseases & Sciences;Mar2011, Vol. 56 Issue 3, p631 

    No abstract available.

  • U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients. Ho, Samuel; Aqel, Bashar; Dieperink, Eric; Liu, Shanglei; Tetrick, Lori; Falck-Ytter, Yngve; DeComarmond, Charles; Smith, Coleman; McKee, Daniel; Boyd, William; Kulig, Clark; Bini, Edmund; Pedrosa, Marcos; Ho, Samuel B; Smith, Coleman I; McKee, Daniel P; Kulig, Clark C; Bini, Edmund J; Pedrosa, Marcos C // Digestive Diseases & Sciences;Mar2011, Vol. 56 Issue 3, p880 

    Background: Patients with chronic hepatitis C genotype 1 (HCV-1) and difficult-to-treat characteristics respond poorly to pegylated interferon alfa and ribavirin (RBV), and could benefit from an interferon with increased activity (consensus interferon or CIFN), favorable viral...

  • Interleukin 28B Polymorphisms and Therapy Response in Egyptian Hepatitis C Genotype-4 Patients. Gouda, Heba M.; El-Saadany, Zainab A.; Foad, Neveen B.; Salama, Rabab M. // DNA & Cell Biology;Sep2014, Vol. 33 Issue 9, p642 

    Hepatitis C infection represents a major health problem in Egypt; only 20% of patients undergo spontaneous clearance of the virus and around 25% of all patients progress to develop cirrhosis. More than 90% of Egyptian patients have hepatitis C virus (HCV) genotype-4. Combined pegylated...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics